Abrocitinib 200 mg ( DrugBank: Abrocitinib )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 84 | サルコイドーシス | 1 |
84. サルコイドーシス
臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05696795 (ClinicalTrials.gov) | May 1, 2023 | 13/1/2023 | Janus Kinase Inhibition in Sarcoidosis | JAK1 Inhibition in Sarcoidosis: an Opportunity for Pathogenesis Directed Therapy | Sarcoidosis | Drug: Abrocitinib 200 mg | Yale University | Pfizer | Not yet recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |